tbuckley/cabot-search huggingface dataset:
Reply to Hertenstein et al. ’s commentary on Yue et al.: Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis
Authors: Jing-Li Yue, Xiang-Wen Chang, Jun-Wei Zheng, Le Shi, Ya-Jie Xiang, Jian-Yu Que, Kai Yuan, Jia-Hui Deng, Teng Teng, Yang-Yang Li, Wei Sun, Hong-Qiang Sun, Michael V. Vitiello, Xiang-Dong Tang, Xin-Yu Zhou, Yan-Ping Bao, Jie Shi, Lin Lu
Journal: Sleep Medicine Reviews (2023)
Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit
Authors: Olawale Akinbobola, Meredith A. Ray, Carrie Fehnel, Andrea Saulsberry, Kourtney Dortch, Matthew Smeltzer, Nicholas R. Faris, Raymond U. Osarogiagbon
Journal: Journal of Thoracic Oncology (2023)
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
Authors: Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, Nicola P. Klein, Anupam B. Kharbanda, Edward Stenehjem, Peter J. Embi, Sarah E. Reese, Allison L. Naleway, Shaun J. Grannis, Malini B. DeSilva, Toan C. Ong, Manjusha Gaglani, Jungmi Han, Monica Dickerson, Bruce Fireman, Kristin Dascomb, Stephanie A. Irving, Gabriela Vazquez-Benitez, Suchitra Rao, Deepika Konatham, Palak Patel, Kristin E. Schrader, Ned Lewis, Nancy Grisel, Charlene McEvoy, Kempapura Murthy, Eric P. Griggs, Elizabeth A. K. Rowley, Ousseny Zerbo, Julie Arndorfer, Margaret M. Dunne, Kristin Goddard, Caitlin Ray, Yan Zhuang, Julius Timbol, Morgan Najdowski, Duck-Hye Yang, John Hansen, Sarah W. Ball, Ruth Link-Gelles
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced viral genomes in the United States, with further Omicron sublineage diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral SARS-CoV-2 strain component plus an updated component of the Omicron BA.4/BA.5 sublineages. On September 1, 2022, a single bivalent booster dose was recommended for adults who had completed a primary vaccination series (with or without subsequent booster doses), with the last dose administered ≥2 months earlier (1). During September 13-November 18, the VISION Network evaluated vaccine effectiveness (VE) of a bivalent mRNA booster dose (after 2, 3, or 4 monovalent doses) compared with 1) no previous vaccination and 2) previous receipt of 2, 3, or 4 monovalent-only mRNA vaccine doses, among immunocompetent adults aged ≥18 years with an emergency department/urgent care (ED/UC) encounter or hospitalization for a COVID-19-like illness.
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study
Authors: Philippa C Lavallée, Hugo Charles, Gregory W Albers, Louis R Caplan, Geoffrey A Donnan, José M Ferro, Michael G Hennerici, Julien Labreuche, Carlos Molina, Peter M Rothwell, Philippe Gabriel Steg, Pierre-Jean Touboul, Shinichiro Uchiyama, Éric Vicaut, Lawrence K S Wong, Pierre Amarenco
Journal: The Lancet Neurology (2023)
Correction to “Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study”
Authors: Jeanine Ursinus, Hedwig D. Vrijmoeth, Margriet G. Harms, Anna D. Tulen, Hans Knoop, Stefanie A. Gauw, Tizza P. Zomer, Albert Wong, Ingrid H.M. Friesema, Yolande M. Vermeeren, Leo A.B. Joosten, Joppe W. Hovius, Bart Jan Kullberg, Cees C. van den Wijngaard
Journal: The Lancet Regional Health - Europe (2023)

[This corrects the article DOI: 10.1016/j.lanepe.2021.100142.].
Family planning considerations in people with multiple sclerosis
Authors: Kristen M Krysko, Ruth Dobson, Raed Alroughani, Maria Pia Amato, Riley Bove, Andrea I Ciplea, Yara Fragoso, Maria Houtchens, Vilija G Jokubaitis, Melinda Magyari, Azza Abdelnasser, Vasantha Padma, Sandra Thiel, Mar Tintore, Sandra Vukusic, Kerstin Hellwig
Journal: The Lancet Neurology (2023)
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial
Authors: Yves Dauvilliers, Michel Lecendreux, Gert Jan Lammers, Patricia Franco, Mikhail Poluektov, Christian Caussé, Isabelle Lecomte, Jeanne Marie Lecomte, Philippe Lehert, Jean Charles Schwartz, Giuseppe Plazzi
Journal: The Lancet Neurology (2023)
Fungal infections: Immune defense, immunotherapies and vaccines
Authors: Jia Tong Loh, Kong-Peng Lam
Journal: Advanced Drug Delivery Reviews (2023)

Invasive fungal infection is an under recognized and emerging global health threat. Recently, the World Health Organization (WHO) released the first ever list of health-threatening fungi to guide research and public health interventions to strengthen global response to fungi infections and antifungal resistance. Currently, antifungal drugs only demonstrate partial success in improving prognosis of infected patients, and this is compounded by the rapid evolution of drug resistance among fungi species. The increased prevalence of fungal infections in individuals with underlying immunological deficiencies reflects the importance of an intact host immune system in controlling mycoses, and further highlights immunomodulation as a potential new avenue for the treatment of disseminated fungal diseases. In this review, we will summarize how host innate immune cells sense invading fungi through their pattern recognition receptors, and subsequently initiate a series of effector mechanisms and adaptive immune responses to mediate fungal clearance. In addition, we will discuss emerging preclinical and clinical data on antifungal immunotherapies and fungal vaccines which can potentially expand our antifungal armamentarium in future.
Magnesium implant degradation provides immunomodulatory and proangiogenic effects and attenuates peri-implant fibrosis in soft tissues
Authors: Heithem Ben Amara, Diana C. Martinez, Furqan A. Shah, Anna Johansson Loo, Lena Emanuelsson, Birgitta Norlindh, Regine Willumeit-Römer, Tomasz Plocinski, Wojciech Swieszkowski, Anders Palmquist, Omar Omar, Peter Thomsen
Journal: Bioactive Materials (2023)

Implants made of magnesium (Mg) are increasingly employed in patients to achieve osteosynthesis while degrading in situ. Since Mg implants and Mg2+ have been suggested to possess anti-inflammatory properties, the clinically observed soft tissue inflammation around Mg implants is enigmatic. Here, using a rat soft tissue model and a 1-28 d observation period, we determined the temporo-spatial cell distribution and behavior in relation to sequential changes of pure Mg implant surface properties and Mg2+ release. Compared to nondegradable titanium (Ti) implants, Mg degradation exacerbated initial inflammation. Release of Mg degradation products at the tissue-implant interface, culminating at 3 d, actively initiated chemotaxis and upregulated mRNA and protein immunomodulatory markers, particularly inducible nitric oxide synthase and toll-like receptor-4 up to 6 d, yet without a cytotoxic effect. Increased vascularization was demonstrated morphologically, preceded by high expression of vascular endothelial growth factor. The transition to appropriate tissue repair coincided with implant surface enrichment of Ca and P and reduced peri-implant Mg2+ concentration. Mg implants revealed a thinner fibrous encapsulation compared with Ti. The detailed understanding of the relationship between Mg material properties and the spatial and time-resolved cellular processes provides a basis for the interpretation of clinical observations and future tailoring of Mg implants.
We need timely access to mental health data: implications of the Goldacre review
Authors: Duncan E Astle, Anna Moore, Louise Marryat, Essi Viding, Karen L Mansfield, Mina Fazel, Matthias Pierce, Kathryn M Abel, Jonathan Green, Ann John, Matthew R Broome, Rachel Upthegrove, Helen Bould, Helen Minnis, Ruchika Gajwani, Madeleine J Groom, Chris Hollis, Elizabeth Liddle, Kapil Sayal, Vashti Berry, Stephan Collishaw, Helen Dawes, Samuele Cortese, Mara Violato, Jack Pollard, James H MacCabe, Sarah-Jayne Blakemore, Emily Simonoff, Edward Watkins, Rachel M Hiller, Ellen Townsend, Cherie Armour, John R Geddes, Lucy Thompson, Matthias Schwannauer, Dasha Nicholls, Matthew Hotopf, Johnny Downs, Atif Rahman, Aditya Narain Sharma, Tamsin J Ford
Journal: The Lancet Psychiatry (2023)
The International Stroke Recovery and Rehabilitation Alliance
Authors: Julie Bernhardt, Dale Corbett, Sean Dukelow, Sean Savitz, John M Solomon, Rachel Stockley, Katharina S Sunnerhagen, Geert Verheyden, Marion Walker, Margit Alt Murphy, Anna Katharina Bonkhoff, Dominique Cadilhac, S Thomas Carmichael, Emily Dalton, Numa Dancause, Jodi Edwards, Coralie English, Erin Godecke, Kate Hayward, Sureshkumar Kamalakannan, Joosup Kim, Gert Kwakkel, Catherine E Lang, Natasha Lannin, Mindy Levin, Elizabeth Lynch, Gillian Mead, Juan Pablo Saa, Nick Ward
Journal: The Lancet Neurology (2023)
GMC is criticised for investments in Nestlé and McDonald’s
Authors: Ronald MacDonald
Journal: BMJ (2023)

Doctors have criticised the General Medical Council after The BMJ found that the regulator had investments in fast food firms, drug companies, private medical insurers, and private healthcare providers. A freedom of information request showed that it has investments totalling nearly £870 000 (€985 000; $1.05m) in the food and soft drink companies Nestlé, McDonald’s, Starbucks, PepsiCo, Coca-Cola, and Unilever, which owns the ice cream brands Magnum, Wall’s, and Ben & Jerry’s. The GMC also invested more than £1.2m in drug companies, including Novo Nordisk, AstraZeneca, Merck, and Roche, more than £470 000 in private insurance or healthcare providers such as Humana Health and UnitedHealth Group, and more than £1.3m in medical device manufacturers, including Edwards Lifesciences, Thermo Fisher Scientific, and Intuitive Surgical, the makers of the da Vinci robotic surgical system (box 1). Box 1 ### Some of GMC’s direct investments as at end of January 2023 #### Fast food #### Pharma #### Medical devicesRETURN TO TEXT
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis
Authors: Noor Samuels, Rob A van de Graaf, Maxim J H L Mulder, Scott Brown, Bob Roozenbeek, Pieter Jan van Doormaal, Mayank Goyal, Bruce C V Campbell, Keith W Muir, Nelly Agrinier, Serge Bracard, Phil M White, Luis San Román, Tudor G Jovin, Michael D Hill, Peter J Mitchell, Andrew M Demchuk, Alain Bonafe, Thomas G Devlin, Adriaan C G M van Es, Hester F Lingsma, Diederik W J Dippel, Aad van der Lugt
Journal: The Lancet Neurology (2023)
Correction: Endoscopic ultrasonography successfully diagnosed pancreas divisum and santorinicele
Authors: Qingyun He, Rui Xie, Xu Li, Shuwen Han, Guoqing Shi, Biguang Tuo, Huichao Wu
Journal: Endoscopy (2023)

Correction to: Endoscopic ultrasonography successfully diagnosed pancreas divisum and santoriniceleEndoscopy 2023; 55(S 01): E527-E528DOI: 10.1055/a-2037-5436
Abstract 2057: Effects Of Levosimendan On Microcirculation In Patients With Cardiogenic Shock
Authors: Roland Wimmer, Matthias Janusch, Henning Lemm, Matthias Winkler, Roland Prondzinsky, Martin Russ, Karl Werdan, Michael Buerke
Journal: Circulation (2008)

Introduction: Cardiogenic shock is characterized by low cardiac output and reduced perfusion pressure with subsequent disturbance of microcirculation. OPS vessel microscopy (orthogonal polarized spectral imaging) is a new method to visualize microcirculation. Methods: In this study 20 Patients with severe cardiogenic shock caused by a myocardial infarction were followed three days after PCI. Group 1 got the conventional catecholamine treatment (norepinephrine and/or dobutamine), and Group 2 received in addition to this common therapy the calcium sensitizer Levosimendan (Simdax®). Five areas in the oral vestibule were recorded and averaged each 24 hours for three days. Data were transferred on a PC and analysed: The average of diameters, of flow and the cell blood velocity (CBV) were recorded. In this way the effects of Levosimendan on microcirculation were observed. Results: An increase of the microcirculatory parameters was observed together with a progressing heart index (HI = 2.4 l/min/m2 on day 1 to HI = 3.5 l/min/m2 on day 3): the averaged vessel diameters went up significantly, also the average flow (p&lt;0.028). In patients treated with Levosimendan microcirculation showed 24 hour infusion an increase in vessel diameters after Levosimendan (27.6 μm to 37.1 μm; p=0.013) as well as an improved flow (387x10 –9ml/s to 1049x10 –9ml/s; p=0.047). CBV also augmented in tendency (480 μm/s to 737 μm/s; p=0.054). Compared to conventionally treated patients, we observed a higher vessel diameter in the Levosimendan treated patients(27,37 μm vs. 34,65 μm; p=0,039) Conclusion: Our data may suggest a benefit for the organ perfusion under Levosimendan treatment. OPS technology could become a new tool to follow shock patients on the intensive care unit in order to analyze therapeutic drug effects on microcirculation.
Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis
Authors: Tarun K. Garg, Ricky D Edmondson, Shweta S. Chavan, Junaid Khan, Susann Szmania, Justin Stivers, Veronica Macleod, Katie Stone, Emily Woods, Donald Johann, Bart Barlogie, Joshua Epstein, Frits van Rhee
Journal: Blood (2013)
Keeping a lid on eosinophil activation
Authors: Heather L. Van Epps
Journal: The Journal of Experimental Medicine (2005)

![Graphic][1] 

Allergic responses (purple) in the lung are increased in Spred-1-deficient mice (bottom).Spred-1 moderates eosinophil activation normally mediated by IL-5, according to a study by Inoue et al. on 

[page 73][2]. Mice lacking Spred-1 have overly exuberant eosinophils and
Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial
Authors: O. Caffo, T. Sava, E. Comploj, M. Giampaolo, F. Zustovich, R. Segati, C. Sacco, A. Perin, G. Pappagallo, F. Valduga
Journal: Journal of Clinical Oncology (2007)

15552 Background: Preclinical data showed a synergism between E and D and several studies supported an advantage in associating E and D. Nevertheless, D is considered a standard treatment for HRPC pts and the role of D+E combination remains controversial. Purpose of this study was to evaluate the activity, in terms of PSA decline (PSA↓), the safety and quality of life (QoL) of D±E in HRPC pts. Methods: Eligibility criteria included: HRPC diagnosis, hormone-refractory advanced disease (PSA progression after at least two hormonal therapy), ECOG PS &lt; 2, adequate renal, hepatic and hematological functions, no prior chemotherapy. Pts were randomized to D 70 mg/m 2 IV d1 q3w (arm A) or D 70 mg/m 2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B). The treatments were planned until best PSA response achievement or PSA progression. Toxicity was recorded according to NCIC criteria. Qol was assessed by self-filled questionnaires during the treatment. Results: Between 04/2003 and 09/2005, 95 pts (median age 69 years, range 48–86, median PSA 80 ng/ml, range 5–2,166 and measurable disease in 45) were randomized to arm A (49) or arm B (46). In arm A, pts received 321 cycles (median 6, range 0–28) with only 13 (4 %) delays = 7 days. In arm B, pts received 338 cycles (median 7, range 0–20) with only 16 (4.7%) delays. Grade 3–4 hematological toxicities consisted of neutropenia, 4% in arm A and 6% in B. One pt in arm B had febrile neutropenia and grade 3 diarrhea. Grade 3–4 non-hematologic toxicities were vomiting (1 pt in both arms), stomatitis (1 pt in arm A and 2 pts in B) and diarrhoea (1 pt in arm B). Two cases of stroke were reported in arm A. No treatment related death was recorded. Responses, in terms of PSA↓ &gt;50% were: 40% in arm A and 75%in arm B with PSA normalization in 5% and 32% respectively. After a median follow-up of 17 months, 65 patients are died (31 in Arm A and 34 in Arm B). Progression free survival (biochemical) was 20 weeks in arm A and 30 in B. Conclusions: D-based regimens are active in HRPC with a manageable toxicity profile. From this preliminary data, DE combination appears promising, in terms of activity and tolerability so, front-to-front formal comparison in a phase III trial can be recommended. No significant financial relationships to disclose.
Changing Patterns of Methaqualone Abuse
Authors: Charles V. Wetli
Journal: JAMA (1983)

Of 246 methaqualone-related deaths identified during an 11-year period (1971 through 1981), 76% have occurred since 1977 and 72% have involved fatal trauma. One third of the victims died in vehicular crashes. Sharp increases in methaqualone-related traumatic suicides, nonvehicular accidents, and homicides have occurred since 1978. This report discusses demographic and toxicological findings, particularly in regard to counterfeit methaqualone. The pattern of fatal methaqualone abuse has changed from an overdose phenomenon in the early 1970s to one of traumatic death. Victims frequently have exhibited poor judgment, impulsive behavior, and somnolence while attempting to function in their environment. The socioeconomic impact of recreational methaqualone abuse should be curtailed by appropriate governmental action and restraint in the prescribing of methaqualone. (<i>JAMA</i>1983;249:621-626)
Self-monitoring of Blood Glucose Levels and Intensified Insulin Therapy
Authors: Mitchell E. Geffner
Journal: JAMA (1983)

Prospective studies have shown that children and adolescents with diabetes have a high prevalence of serious complications and a sharp reduction in life expectancy. Recently, self-monitoring of blood glucose levels has become available and, for the first time, provides a method for determining the concentration of blood glucose with considerable accuracy. We have introduced this method of control assessment to our pediatric diabetic patient population in conjunction with a program of intensified insulin administration (two or more injections per day). This is a report of the ready acceptance of these methods by children and adolescents and their parents (53/63, or 84%). The effectiveness of this program is evidenced by a progressive and significant reduction in the percentage of glycosylated hemoglobin during a period of 18 months in a majority of the subjects. These observations suggest that improved glycemic control can be achieved in young diabetics by using multiple insulin injections and self-monitoring of blood glucose levels. Whether such control can lead to a better long-term outlook for diabetics remains to be seen. (<i>JAMA</i>1983;249:2913-2916)
Childhood Lead Poisoning
Authors: Sue Binder
Journal: JAMA (1993)

Exposure of children to lead remains a pervasive problem in the United States. The US Environmental Protection Agency estimates that in 1990 approximately 3 million children in the United States had blood lead levels high enough to affect intelligence and development (whole blood lead level ≥0.48 μmol/L [10 μg/dL]).<sup>1</sup>The residential use of lead-based paint was prohibited in 1978,<sup>2</sup>and lead use in gasoline has decreased dramatically since the early 1970s.<sup>3</sup>Nevertheless, approximately 74% of all housing units built before 1980 contain lead-based paint,<sup>2</sup>and dust and soil heavily contammated by lead-based paint or leaded gasoline used in the past are found throughout the country.<sup>1</sup> The results of the two studies on lead published in this issue of<i>JAMA</i><sup>4,5</sup>make important contributions to our understanding of the impact of secondary prevention—the identification of and treatment for children with blood lead levels of public health
Shoulder Enlargement as the Presenting Sign in Syringomyelia
Authors: J. Chris Sackellares
Journal: JAMA (1976)

Two adult patients had painful enlargement of the shoulder and complete destruction of the humeral head. Angiograms of the shoulder showed highly vascular lesions in both patients. Both patients had syringomyelia, for which the swollen shoulder was the first manifestation. (<i>JAMA</i>236:2878-2879, 1976)
Contents
Authors: B Yeoh, M Vijay-Kumar, L.-Y Mak, E Gane, C Schwabe, K Yoon, J Heo, R Scott, J.-H Lee, Y Kweon, M Weltman, S Harrison, B Neuschwander-Tetri, K Cusi, R Loomba, B Given, D Christianson, E Garcia-Medel, M Yi, J Hamilton, M.-F Yuen, A Sanyal, S Williams, J Lavine, L Alexander, R Ostroff, H Biegel, K Kowdley, N Chalasani, S Dasarathy, A Diehl, B Hameed, C Behling, D Kleiner, S Karpen, J Williams, Y Jia, K Yates, J Tonascia, F Zhang, L.-D Xu, Q Zhang, A Wang, X Yu, S Liu, C Chen, S Wu, J Jin, A Lin, D Neculai, B Zhao, X.-H Feng, T Liang, P Xu, Y.-W Huang, J Su, L Brunner, E Ates Oz, J Sacherl, G Frank, H Kerth, F Thiele, M Wiegand, C Mogler, J Aguilar, P Knolle, N Collin, A Kosinska, U Protzer, C Adraneda, Y Tan, E Yeo, G Kew, A Khakpoor, S Lim, L Wang, Q Zhu, J Zhang, Y Zhang, X Ni, K Xiang, J Jiang, B Li, Y Yu, H Hu, M Zhang, W Wu, J Zeng, Z Yan, J Dai, K Sun, X Zhang, D Chen, S Feng, L Sach-Peltason, J Young, L Gao, R Ji, J Chen, Y Xie, X Dou, B Qing, Z Liu, Y Lu, L Dang, X Zhu, Y Sun, X Zheng, L Zhang, D Guo, Y Chen, Y Liu, Z Xun, K Ma, S Liang, X Li, S Zhou, L Sun, Y Du, X Guo, T Cui, H.-Z Zhou, J Wang, D Yin, R Song, S Zhang, W Cai, F Meng, H Guo, B Zhang, D Yang, R Bao, Q Hu, Y Ye, L Liu, A Schlegel, M Mueller, X Muller, J Eden, R Panconesi, S Von Felten, K Steigmiller, R Sousa, Da Silva, O De Rougemont, J.-Y Mabrut, M Lesurtel, M Cerisuelo, N Heaton, M Allard, R Adam, D Monbaliu, I Jochmans, M Haring, R Porte, A Parente, P Muiesan, P Kron, M Attia, D Kollmann, G Berlakovich, X Rogiers, K Petterson, A Kranich, S Amberg, B Müllhaupt, P.-A Clavien, P Dutkowski, P Burra, F Tacke, V Ratziu, S Zeuzem, B Sangro, P Angeli, J Kellum, M Nadim, D Samuel, R Morikawa, N Nakamoto, T Amiya, P.-S Chu, Y Koda, T Teratani, T Suzuki, Y Kurebayashi, A Ueno, N Taniki, K Miyamoto, A Yamaguchi, S Shiba, T Katayama, K Yoshida, Y Takada, R Ishihara, H Ebinuma, M Sakamoto, T Kanai, S.-T Cheng, J.-L Hu, J.-H Ren, H.-B Yu, S Zhong, V Wong, B Kwan Law, W.-X Chen, H.-M Xu, Z.-Z Zhang, X.-F Cai, Y Hu, W.- L Zhang, Q.-X Long, F Ren, A.-L Huang, J Howell, A Pedrana, S Schroeder, N Scott, L Aufegger, R Atun, R Baptista-Leite, G Hirnschall, E 't Hoen, S Hutchinson, J Lazarus, L Olufunmilayo, R Peck, M Sharma, A Sohn, A Thompson, M Thursz, D Wilson, M Hellard, S.-Y Cai, D Yu, C Soroka, J Boyer, D Chand, F Mohr, H Mcmillan, F Tukov, K Montgomery, A Kleyn, R Sun, S Tauscher-Wisniewski, P Kaufmann, G Kullak-Ublick, T Marjot, A Moon, J Cook, S Abd-Elsalam, C Aloman, M Armstrong, E Pose, E Brenner, T Cargill, M.-A Catana, R Dhanasekaran, A Eshraghian, I García-Juárez, U Gill, P Jones, J Kennedy, A Marshall, C Matthews, G Mells, C Mercer, P Perumalswami, E Avitabile, X Qi, F Su, N Ufere, Y Wong, M.-H Zheng, E Barnes, A Barritt, G Webb
Journal: Journal of Hepatology (2023)
JHEP at a glance (April 2023)
Authors: Yi Mak, Ed Gane, Christian Schwabe, Min Yi, James Hamilton, Man-Fung Yuen, Ki Yoon, Jeong Heo, Russell Scott, Jeong-Hoon Lee, Jung Lee, Young Kweon, Martin Weltman, Stephen Harrison, Brent Neuschwander-Tetri, Kenneth Cusi, Rohit Loomba, Bruce Given, Dawn Christianson, Eric Garcia-Medel, Man Fung, Yuen Jhepatol, Arun Sanyal, Stephen Williams, Joel Lavine, Yi Jia, Katherine Yates, James Tonascia
Journal: Journal of Hepatology (2023)